Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Olympus, Ultivue comarketing agreement

February 2020—Olympus and Ultivue, a developer of tissue biomarker identification and quantification assays for translational research, have entered into a comarketing agreement. The partnership will provide a solution for fluorescent multiplexing by combining the Olympus Slideview VS200 automated slide scanner with Ultivue’s proprietary InSituPlex DNA barcoding and staining technology to provide quantitative colocalization analysis in fluorescent whole slide images.

SeraCare launches TMB reference materials

February 2020—SeraCare Life Sciences launched genomic DNA and formalin-fixed, paraffin-embedded reference materials for tumor mutational burden measurement by next-generation sequencing assays. SeraCare collaborated with Friends of Cancer Research and International Quality Network for Pathology in the development and evaluation of a range of gDNA and FFPE-based TMB reference materials across different targeted NGS panels, sequencing platforms, and bioinformatics analysis pipelines.

FDA approves first vaccine for Ebola virus

February 2020—The U.S. Food and Drug Administration announced the approval of Ervebo (Merck), the first FDA-approved vaccine for the prevention of Ebola virus disease, caused by Zaire ebolavirus, in people 18 years of age and older. Ervebo is administered as a single-dose injection and is a live, attenuated vaccine that has been genetically engineered to contain a protein from the Zaire ebolavirus.

Applied BioCode panel gets FDA clearance

February 2020—Applied BioCode has received FDA 510(k) clearance for its BioCode Respiratory Pathogen Panel for use on the company’s BioCode MDx-3000 system. The panel tests nasopharyngeal swabs for common viruses and bacteria, including influenza A and subtypes H1, H1N1 2009pdm, and H3; influenza B; respiratory syncytial virus A/B; parainfluenza virus types 1–4; human metapneumovirus A/B; adenovirus; rhinovirus/enterovirus; coronavirus (229E, NL63, OC43, and HKU1); Mycoplasma pneumoniae; Chlamydia pneumoniae; and Bordetella pertussis.

FDA clears Simplexa VZV Swab Direct

February 2020—DiaSorin Molecular has received FDA clearance for its Simplexa VZV Swab Direct assay. The CLIA moderate-complexity assay is designed for use on the Liaison MDX instrument to detect varicella-zoster virus DNA from cutaneous and mucocutaneous swab specimens. The assay complements the company’s Simplexa VZV Direct kit, which is for use with cerebrospinal fluid samples.

Baebies Finder gets CE mark

February 2020—Baebies announced that its Finder platform is CE marked as an in vitro diagnostic device and commercially available in Europe and other countries that recognize the CE mark. The platform includes an instrument and a cartridge, which tests for glucose-6-phosphate dehydrogenase from 50 μL of whole blood. Features of the platform include an eight-inch-wide footprint, preloaded consumables with all necessary reagents, and a turnaround time of approximately 15 minutes from sample introduction.

NeuMoDx, Sentinel partnership

February 2020—NeuMoDx Molecular and Sentinel Diagnostics announced a partnership to develop diagnostic assays for the NeuMoDx 96 and 288 molecular systems. Sentinel’s real-time PCR assays will be adapted to the NeuMoDx 96 and 288 molecular systems and will incorporate Sentinel’s STAT-NAT technology, which provides the ability to stabilize the activity of a PCR mix, allowing room-temperature storage and transport. The test menu pipeline for the systems will include assays to detect and monitor post-transplant infections, parasitic and hospital-acquired infections, and respiratory infections, and for pharmacogenetics applications.

Qiagen panels for simultaneous DNA, RNA analysis

February 2020—Qiagen introduced QIAseq Multimodal Panels, which offer a consolidated workflow to enrich DNA variants, RNA fusions, and gene expression levels from a single sample, with input as low as 10 ng of total nucleic acid. It reduces the workflow to approximately nine hours, the company reports, by eliminating the need for two workflows from separate DNA and RNA samples.

Codexis, Roche license agreement

February 2020—Codexis, a protein engineering company, announced a license agreement to provide Roche with its EvoT4 DNA ligase high-performance molecular diagnostic enzyme. The enzyme was developed using Codexis’ CodeEvolver protein engineering platform and is expected to be incorporated into Roche’s next-generation sequencing library preparation kits and other sequencing products. The license grants Roche worldwide rights to include the EvoT4 DNA ligase in its nucleic acid sequencing products and workflows.

FDA clears Curetis Unyvero LRT for BAL specimens

February 2020—Curetis announced it has received FDA 510(k) clearance to market its Unyvero LRT Lower Respiratory Tract application cartridge for use with bronchoalveolar lavage samples to diagnose lower respiratory tract infections such as pneumonia.

MARKETPLACE

TRENDING